Document is current
Any future updates will be listed below
-
Authors
,
Meyer, Elias Laurin
Mesenbrink, Peter
Mielke, Tobias
Parke, Tom
Evans, Daniel
König, Franz https://orcid.org/0000-0002-6893-3304
-
Funding
Funding for this research was provided by:
Novartis
Innovative Medicines Initiative (IMI) 2 Joint Undertaking (853966)
- License Information
-
More Information
Article History
Received: 9 September 2020
Accepted: 13 February 2021
First Online: 4 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The research of Elias Laurin Meyer was funded by Novartis on the university and not an individual level. Peter Mesenbrink is an employee of Novartis Pharmaceuticals Corporation who is a member of the consortium and owns shares of stock in the company. Tobias Mielke declares an interest as shareholder of ICON PLC who license the ADDPLAN software commercially and as an employee of Janssen. Tom Parke declares an interest as an employee of Berry Consultants who license the FACTS software commercially. Dan Evans declares a competing interest as a Pfizer employee. FK reports grants from Novartis Pharma AG during the conduct of the study and grants from Merck KGaA outside the submitted work.
